Limits...
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.

Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K - Stroke (2015)

Bottom Line: A model-based cost-utility analysis was performed using a lifetime horizon.A Markov model was constructed and populated with probabilities, outcomes, and cost data from published sources, including 1-way and probabilistic sensitivity analysis.This is an important factor for consideration in deciding whether to commission this intervention.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK (J.G., D.A.); Department of Applied Health Research, University College London, London, UK (E.P., S.M.); Department of Market Access, Pricing and Outcomes Research, Boehringer Ingelheim Ltd, Bracknell, Berks, UK (T.S.); and Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK (K.L.).

Show MeSH

Related in: MedlinePlus

Decision model. A, Short-run analytic model. B, Long-run Markov model structure. IV-tPA indicates intravenous tissue-type plasminogen activator; and mRS, modified Rankin Scale.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4542565&req=5

Figure 1: Decision model. A, Short-run analytic model. B, Long-run Markov model structure. IV-tPA indicates intravenous tissue-type plasminogen activator; and mRS, modified Rankin Scale.

Mentions: A short-run decision analytic model (Figure 1A) was created to analyze data on costs and clinical outcomes within 3 months from stroke and subsequently was used to distribute a theoretical cohort of patients into 1 of 3 possible health states (see Outcomes). A long-run Markov state-transition model was then used to estimate the expected costs and outcomes over a life-time horizon of 20 years, using cycles of 3 months (Figure 1B). The analysis was undertaken from the perspective of the UK National Health Service and Personal Social Services. Costs were calculated in 2013–2014 UK pounds and are presented in US$ using an exchange rate of £1=US$1.65.28 Where appropriate, costs were converted to 2013–2014 prices using National Health Service Pay and Prices Indices.29 Outcomes are measured in terms of deaths averted and quality adjusted life years (QALYs) gained. In the long-run model, all costs and outcomes after the first year are discounted at an annual rate of 3.5%.27


Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.

Ganesalingam J, Pizzo E, Morris S, Sunderland T, Ames D, Lobotesis K - Stroke (2015)

Decision model. A, Short-run analytic model. B, Long-run Markov model structure. IV-tPA indicates intravenous tissue-type plasminogen activator; and mRS, modified Rankin Scale.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4542565&req=5

Figure 1: Decision model. A, Short-run analytic model. B, Long-run Markov model structure. IV-tPA indicates intravenous tissue-type plasminogen activator; and mRS, modified Rankin Scale.
Mentions: A short-run decision analytic model (Figure 1A) was created to analyze data on costs and clinical outcomes within 3 months from stroke and subsequently was used to distribute a theoretical cohort of patients into 1 of 3 possible health states (see Outcomes). A long-run Markov state-transition model was then used to estimate the expected costs and outcomes over a life-time horizon of 20 years, using cycles of 3 months (Figure 1B). The analysis was undertaken from the perspective of the UK National Health Service and Personal Social Services. Costs were calculated in 2013–2014 UK pounds and are presented in US$ using an exchange rate of £1=US$1.65.28 Where appropriate, costs were converted to 2013–2014 prices using National Health Service Pay and Prices Indices.29 Outcomes are measured in terms of deaths averted and quality adjusted life years (QALYs) gained. In the long-run model, all costs and outcomes after the first year are discounted at an annual rate of 3.5%.27

Bottom Line: A model-based cost-utility analysis was performed using a lifetime horizon.A Markov model was constructed and populated with probabilities, outcomes, and cost data from published sources, including 1-way and probabilistic sensitivity analysis.This is an important factor for consideration in deciding whether to commission this intervention.

View Article: PubMed Central - PubMed

Affiliation: From the Department of Stroke Medicine, Imperial College Healthcare NHS Trust, London, UK (J.G., D.A.); Department of Applied Health Research, University College London, London, UK (E.P., S.M.); Department of Market Access, Pricing and Outcomes Research, Boehringer Ingelheim Ltd, Bracknell, Berks, UK (T.S.); and Imaging Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK (K.L.).

Show MeSH
Related in: MedlinePlus